zuma-1 update: durable survival in r/r dlbcl patients treated with axi-cel
Published 5 years ago • 105 plays • Length 2:32Download video MP4
Download video MP3
Similar videos
-
1:34
zuma-1 update: safety data of axi-cel in patients with r/r dlbcl
-
2:55
updates from zuma-7: axi-cel for r/r dlbcl
-
6:37
zuma-7: axi-cel in r/r large b-cell lymphoma
-
1:41
zuma-1: 3-year follow-up on axi-cel in lbcl patients
-
4:03
axi-cel plus rituximab for r/r lbcl and updates from the zuma-14 study
-
1:01:19
june 29, vmr with rabih & cps team - aki
-
26:31
survival analysis overview
-
5:54
zuma-5 update: axicabtagene ciloleucel continues to show strong effect in r/r inhl
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
2:26
zuma-5: high orr and cr for r/r inhl with axi-cel
-
2:06
car-t in dlbcl: 4-year follow-up data from zuma-1
-
1:08
zuma-7: overall survival benefit of axi-cel over soc in second-line lbcl
-
3:46
zuma-5 update: retreatment of r/r inhl with axi-cel
-
2:52
zuma-24 preliminary analysis of axi-cel in the outpatient setting in patients with r/r lbcl
-
1:11
zuma-11 study overview: axi-cel plus utomilumab in r/r dlbcl
-
2:48
zuma-1: safety and efficacy of axicabtagene in refractory non-hodgkin lymphoma patients
-
0:54
zuma-3 end of phase i results: axi-cel for r/r all
-
1:15
primary overall survival analysis of the zuma-7 trial
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
4:44
zuma-7 subgroup analysis: axi-cel vs soc in elderly patients with r/r lbcl
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
2:24
zuma-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; kte-c19) in patients with nhl